Abstract
The atypical neuroleptics, clozapine and olanzapine, have superior therapeutic efficacy against the negative symptoms of schizophrenia, compared with the typical neuroleptics. Recently, it has been suggested that the ability of clozapine and olanzapine to induce Fos expression in the medial prefrontal cortex (mPFC), contribute to their therapeutic efficacy. However, the mechanisms underlying the neuropharmacological effects of clozapine and olanzapine in the mPFC remain elusive. In the present study, we demonstrate that clozapine- and olanzapine-induced Fos expression in the mPFC are inhibited by propranolol. We also show that clozapine and olanzapine induce Fos expression in the locus coeruleus. These results suggest that clozapine and olanzapine increase noradrenaline release by stimulating noradrenergic neuronal activity in the locus coeruleus and, consequently, increased noradrenaline induce Fos expression in the mPFC via β-adrenergic receptors. This postulated sequence may be one of mechanisms by which clozapine-like atypical neuroleptics are more effective for the negative symptoms of schizophrenia.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Ackenheil M . (1989): Clozapine: Pharmacokinetic investigation and biochemical effects in man. Psychopharmacology 99: S32–S37
Ader J P, Sebens J B, Korf J . (1980): Central levels of noradrenaline, 3-methoxy-4-hydroxyphenylethyleneglycol and cyclic AMP in the rat after activation of locus coeruleus neurons: Influence of single and repeated neuroleptic treatment. Psychopharmacology 70: 239–245
Beasley CM, Tollefson G, Tran P, Sattterlee W, Sanger T, Hamilton S . (1996): Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind trial. Neuropsychopharmacology 14: 111–123
Bing G, Stone E A, Zhang Y, Filer D . (1992): Immunohistochemical studies of noradrenergic-induced expression of c-fos in the rat CNS. Brain Res 592: 57–62
Bolden C, Cusack B, Richelson E . (1991): Clozapine is a potent and selective muscarinic antagonist at the five cloned human muscarinic acetylcholine receptors expressed in CHO-K1 cells. Eur J Pharmacol 192: 205–206
Breier A, Buchanan RW, Waltrip RW II, Listwak S, Holmes C, Goldstein DS . (1994): The effect of clozapine on plasma norepinephrine: Relationship to clinical efficacy. Neuropsychopharmacology 10: 1–7
Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT . (1996a): Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14: 87–96
Bymaster FP, Hemrick-Luecke SK, Perry KW, Fuller RW . (1996b): Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, α1-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology 124: 87–94
Cedarbaum JM, Aghajanian GK . (1977): Catecholamine receptors on locus coeruleus neurons: Pharmacological characterization. Eur J Pharmacol 44: 375–385
Claghorn J, Honigfeld G, Abuzzahab FS, Steinbook AR, Tuason V, Klerman G . (1987): The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 7: 377–384
Cohen RM, Aulakh C, McLellan C, Murphy DL . (1985): 6-Hydroxydopamine pretreatment effects on α- and β-adrenergic receptor adaptation to clorgyline. Naunyn-Schmiedeberg's Arch Pharmacol 329: 158–161
Coward DM . (1992): General pharmacology of clozapine. Br J Psychiatry 160(Suppl 17):5–11
Deutch AY, Duman RS . (1996): The effects of antipsychotic drugs on Fos protein expression in the prefrontal cortex: Cellular localization and pharmacological characterization. Neuroscience 70: 377–389
Dragunow M, Faull R . (1989): The use of c-fos as a metabolic marker in neuronal pathway tracing. J Neurosci Meth 29: 261–265
Fink-Jensen A, Kristensen P . (1994): Effects of typical and atypical neuroleptics on Fos protein expression in the rat forebrain. Neurosci Lett 182: 115–118
Fink-Jensen A, Ludvigsen T S, Korsgaard N . (1995): The effect of clozapine on Fos protein immunoreactivity in the rat forebrain is not mimicked by the addition of α1-adrenergic or 5HT2 receptor blockade to haloperidol. Neurosci Lett 194: 77–80
Freedman JE, Aghajanian GK . (1984): Idazoxan (RX 781094) selectively antagonizes α2-adrenoceptors on rat central neurons. Eur J Pharmacol 105: 265–272
Gobert A, Rivet JM, Audinot V, Newman-Tancredi A, Cistarelli L, Millan MJ . (1998): Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto-and heteroreceptor-mediated control of release. Neuroscience 84: 413–429
Grant SJ, Bittman K, Benno RH . (1992): Both phasic sensory stimulation and tonic pharmacological activation increase Fos-like immunoreactivity in the rat locus coeruleus. Synapse 12: 112–118
Guo N, Klitenic MA, Tham CS, Fibiger HC . (1995): Receptor mechanisms mediating clozapine-induced c-fos expression in the forebrain. Neuroscience 65: 747–756
Hamamura T, Lee Y, Fujiwara Y, Kuroda S . (1997): Serotonin 1A receptor agonists induce Fos protein expression in the locus coeruleus of the conscious rat. Brain Res 759: 156–159
Hamilton SH, Revicki DA, Genduso LA, Beasley CM . (1998): Olanzapine versus placebo and haloperidol: Quality of life and efficacy results of the North American double-blind trial. Neuropsychopharmacology 18: 41–49
Holes VR . (1990): The anatomy and function of noradrenaline in the mammalian brain. In Heal DJ, Marsden CA (eds), The pharmacology of noradrenaline in the central nervous system. Oxford, Oxford University Press, pp 1–40
Kane J, Honigfeld G, Singer J, Meltzer H . (1988): Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45: 789–796
Kurokawa K, Narita M, Koshiya K, Hidaka K, Ohmori J, Satoh K . (1997): Effects of YM-43611, a novel dopamine D2-like receptor antagonist, on immediate early gene expression in the rat forebrain. Neuropsychopharmacology 17: 27–33
L'Heureux R, Dennis T, Curet O, Scatton B . (1986): Measurement of endogenous noradrenaline release in the rat cerebral cortex in vivo by transcortical dialysis: Effects of drugs affecting noradrenergic transmission. J Neurochem 46: 1794–1801
Li X-M, Perry KW, Wong DT, Bymaster FP . (1998): Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum. Psychopharmacology 136: 153–161
Litman RE, Hong WW, Weissman EM, Su T-P, Potter WZ, Pickar D . (1993): Idazoxan, an α2 antagonist, augments fluphenazine in schizophrenic patients: A pilot study. J Clin Psychopharmacol 13: 264–267
Litman RE, Su T-P, Potter WZ, Hong WW, Pickar D . (1996): Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia, comparison with the atypical neuroleptic, clozapine. Br J Psychiatry 168: 571–579
Meltzer HY, Matsubara S, Lee JC . (1989): Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin 2 pKi values. J Pharmacol Exp Ther 251: 238–246
Parnavelas JG . (1990): Neurotransmitters in the cerebral cortex. In Uylings HBM, Van Eden CG, De Bruin JPC, Corner MA, Feenstra MGP (eds), The Prefrontal Cortex. Progress in Brain Research. Vol. 85. Amsterdam, Elsevier, pp 13–29
Paxinos G, Watson C . (1986): The Rat Brain in Stereotaxic Coordinates. 2nd ed. Sydney, Academic Press
Picker D, Owen RR, Litman RE, Konicki PE, Gutierrez R, Rapaport MH . (1992): Clinical and biologic response to clozapine in patients with schizophrenia: Crossover comparison with fluphenazine. Arch Gen Psychiatry 49: 345–353
Ramirez OA, Wang RY . (1986): Locus coeruleus norepinephrine-containing neurons: Effects produced by acute and subchronic treatment with antipsychotic drugs and amphetamine. Brain Res 362: 165–170
Rao ML, Moller HJ . (1994): Biochemical findings of negative symptoms in schizophrenia and their putative relevance to pharmacologic treatment. Neuropsychobiology 30: 160–172
Robertson GS, Fibiger HC . (1992): Neuroleptics increase c-fos expression in the forebrain: Contrasting effects of haloperidol and clozapine. Neuroscience 46: 315–328
Robertson GS, Matsumura H, Fibiger HC . (1994): Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther 271: 1058–1066
Robertson GS, Fibiger HC . (1996): Effects of olanzapine on regional c-fos expression in rat forebrain. Neuropsychopharmacology 14: 105–110
Rollema H, Lu Y, Schmidt AW, Zorn SH . (1997): Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Eur J Pharmacol 338: R3–R5
Sagar SM, Sharp FR, Curran T . (1988): Expression of c-fos protein in brain: Metabolic mapping at the cellular level. Science 240: 1328–1331
Sebens JB, Koch T, Ter Horst GT, Korf J . (1998): Olanzapine-induced Fos expression in the rat fore brain; cross-tolerance with haloperidol and clozapine. Eur J Pharmacol 353: 13–21
Sharp FR, Sagar SM, Swanson RA . (1993): Metabolic mapping with cellular resolution: c-fos vs. 2-deoxyglucose. Crit Rev Neurobiol 7: 205–228
Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC . (1990): Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347: 146–151
Stone EA, Zhang Y . (1995): Adrenoceptor antagonists block c-fos response to stress in the mouse brain. Brain Res 694: 279–286
Van Kammen DP, Van Kammen WB, Mann LS, Seppala T, Linnoila M . (1986): Dopamine metabolism in the cerebrospinal fluid of drug-free schizophrenic patients with and without cortical atrophy. Arch Gen Psychiatry 43: 978–983
Van Tol HHM, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB, Civelli O . (1991): Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350: 610–614
Van Veldhuizen MJ, Feenstra MG, Boer GJ . (1994): Regional differences in the in vivo regulation of the extracellular levels of noradrenaline and its metabolites in rat brain. Brain Res 635: 238–248
Wan W, Ennulat DJ, Cohen BM . (1995): Acute administration of typical and atypical antipsychotic drugs induces distinctive patterns of Fos expression in the rat forebrain. Brain Res 688: 95–104
Weinberger DR . (1988): Schizophrenia and the frontal lobe. Trends Neurosci 8: 367–370
Weinberger DR, Berman KF, Illowsky BP . (1988): Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. Arch Gen Psychiatry 45: 609–615
Westerink BHC, de Boer P, de Vries JB, Kruse CG, Long SK . (1998): Antipsychotic drugs induce similar effects on the release of dopamine and noradrenaline in the medial prefrontal cortex of the rat brain. Eur J Pharmacol 361: 27–33
Wolkin A, Sanfilipo M, Wolf A P, Angrist B, Brodie J D, Rotrosen J . (1992): Negative symptoms and hypofrontality in chronic schizophrenia. Arch Gen Psychiatry 49: 959–965
Acknowledgements
This work was supported by a Research Grant (No. 08770770) from the Japanese Ministry of Education in 1996 and a research grant from Zikei Hospital in 1999.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ohashi, K., Hamamura, T., Lee, Y. et al. Clozapine- and Olanzapine-induced Fos Expression in the Rat Medial Prefrontal Cortex is Mediated by β-Adrenoceptors. Neuropsychopharmacol 23, 162–169 (2000). https://doi.org/10.1016/S0893-133X(00)00105-6
Received:
Revised:
Accepted:
Issue date:
DOI: https://doi.org/10.1016/S0893-133X(00)00105-6
Keywords
This article is cited by
-
Elevation of EGR1/zif268, a Neural Activity Marker, in the Auditory Cortex of Patients with Schizophrenia and its Animal Model
Neurochemical Research (2022)
-
Effects of central activation of serotonin 5-HT2A/2C or dopamine D2/3 receptors on the acute and repeated effects of clozapine in the conditioned avoidance response test
Psychopharmacology (2015)
-
Cortico-Subcortical Neuromodulation Involved in the Amelioration of Prepulse Inhibition Deficits in Dopamine Transporter Knockout Mice
Neuropsychopharmacology (2012)
-
Propranolol blocks chronic risperidone treatment-induced enhancement of spatial working memory performance of rats in a delayed matching-to-place water maze task
Psychopharmacology (2007)
-
Dopamine and incentive learning: A framework for considering antipsychotic medication effects
Neurotoxicity Research (2006)
